PD-L1 immunohistochemistry is mandatory for the decision proimmunooncogenic or contraimmunooncogenic treatment in tumors of different organs, for example, bladder cancer, lung cancer, or breast cancer [4, 35–38]. This evidence concerns the gene CD274 and lung cancer.